MXC vs. CHLL, PXS, STX, HELD, CNSL, BVX, IMM, FDBK, POLX, and PRM
Should you be buying Argent BioPharma stock or one of its competitors? The main competitors of Argent BioPharma include Chill Brands Group (CHLL), Provexis (PXS), Shield Therapeutics (STX), Hellenic Dynamics (HELD), Cambridge Nutritional Sciences (CNSL), BiVictriX Therapeutics (BVX), ImmuPharma (IMM), Feedback (FDBK), Polarean Imaging (POLX), and Proteome Sciences (PRM). These companies are all part of the "medical" sector.
Argent BioPharma (LON:MXC) and Chill Brands Group (LON:CHLL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Chill Brands Group has lower revenue, but higher earnings than Argent BioPharma. Chill Brands Group is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Chill Brands Group had 2 more articles in the media than Argent BioPharma. MarketBeat recorded 2 mentions for Chill Brands Group and 0 mentions for Argent BioPharma. Chill Brands Group's average media sentiment score of 0.46 beat Argent BioPharma's score of 0.00 indicating that Chill Brands Group is being referred to more favorably in the news media.
Argent BioPharma's return on equity of 0.00% beat Chill Brands Group's return on equity.
Chill Brands Group received 6 more outperform votes than Argent BioPharma when rated by MarketBeat users.
Argent BioPharma has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Chill Brands Group has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
1.2% of Argent BioPharma shares are held by institutional investors. Comparatively, 0.0% of Chill Brands Group shares are held by institutional investors. 8.2% of Argent BioPharma shares are held by company insiders. Comparatively, 24.0% of Chill Brands Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Chill Brands Group beats Argent BioPharma on 8 of the 13 factors compared between the two stocks.
Get Argent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for MXC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Argent BioPharma Competitors List
Related Companies and Tools
